<DOC>
	<DOCNO>NCT00092976</DOCNO>
	<brief_summary>The primary objective clinical research study evaluate safety efficacy ReFacto subject hemophilia A undergoing major surgery monitor use chromogenic substrate assay local laboratory .</brief_summary>
	<brief_title>Study Evaluating ReFacto® Hemophilia A Undergoing Major Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Age ≥ 6 year Male previously treat patient ( ≥150 Exposure Days ) moderate severe hemophilia A ( i.e . ≤ 5 % FVIII : C ) undergo elective major surgery anticipate require least 6 consecutive day daily factor VIII ( FVIII ) infusion ( surgical postsurgical prophylaxis ) Ability adhere protocol requirement Hypersensitivity ReFacto , murine allergen , hamster allergen 2 History FVIII inhibitor current inhibitor , define &gt; 0.6 BU Prior participation study Any concomitant bleeding disorder hemophilia A</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>